The use of a new pharmaceutical preparation for treatment of OAB
Current treatments of overactive bladder disease (OAB) with oral medications show high discontinuation rates due to significant side effects and/or limited efficacy.
Based on the need for more effective medicines to treat OAB we have developed a proprietary dissolvable ovulum based on the work of Prof. Grant S. Mulholland, that allows the local administration of drugs through the epithelium of urethra of women. With this survey we would like to assess clinicians’ and patients’ view on the use of such a dissolvable, urethral ovulum for OAB.
We would be very grateful if you could dedicate 5-7 minutes of your time to answer the following questions.
Sample shape of the urethral ovulum designed according to urethral anatomy
Are you a clinician specialized in urology, gynecology, urogynecology or related fields?
No, I am an OAB patient or close to someone suffering from OAB
None of the above
Page 1 of 4
Never submit passwords through Google Forms.
This content is neither created nor endorsed by Google.
Terms of Service